Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Says Mr Yoshiwaka to Become Espha President
March 8, 2012
- MTPC Enters into Agreement for Joint Research of New Vaccines with Canadian Company
March 8, 2012
- US FDA Does Not Approve Additional Indication of AML for Eisai’s Dacogen
March 8, 2012
- “Absolutely No Intention” of Moving Headquarters from Osaka: President Teshirogi of Shionogi
March 8, 2012
- The Earthquake-Hit Regions Today 2: “Irregular Visits” Still Continue for MRs Faced With “Fukushima”
March 8, 2012
- MTPC, Daiichi Sankyo Form Strategic Alliance to Jointly Market 2 Diabetes Treatments
March 7, 2012
- Use of Aricept Generics Is Likely to Expand to Nursing Homes: Pharmacist Survey
March 7, 2012
- The Earthquake-Hit Regions Today 1: Difficulties in Securing Pharmacists, Need for Long Sustained Support
March 7, 2012
- Price Reduction Rates for 4 Major Generics Manufacturers at 8.9% to 12.2%: Jiho Survey
March 7, 2012
- Takeda US Subsidiary Millennium Begins International PIII Trial on Alisertib
March 7, 2012
- Long-Listed Drugs Account for Over 60% of Eisai’s Sales: Jiho Survey
March 7, 2012
- Worldwide Sales by Biopharmaceutical Contract Manufacturers Down Slightly in 2010 at US$3.4 Billion: Seed Planning
March 7, 2012
- Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
- Daiichi Sankyo, GSK Agree to Set Up Joint Venture in Vaccine Business
March 5, 2012
- Novartis Most Admired Pharmaceutical Company in IAL Survey; Will “MR quality” Be Its Achilles’ Heel?
March 5, 2012
- ReproCELL to Change Model of Drug Discovery by Launching World’s 1st iPS Cell-derived Hepatocytes
March 5, 2012
- Sanofi-aventis Nichi-Iko Withholds NHI Price Listing of Authorized Allegra Generic in June
March 2, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…